| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
YSL has immune-suppressive properties that include boosting the proliferation of mouse splenic lymphocytes produced by concanavalin (ConA), phagocytosing mouse peritoneal macrophages, and natural killer (NK) cell activity [1]. Tyroserleutide (YSL) is an immunotherapy tripeptide that, by down-regulating the expression of cyclin D1 and Bcl-2, can induce the apoptosis of liver cancer cells (H22) [2]. Tyroserleutide is the best option for causing liver tumor cells to undergo apoptosis [2]. Tyroserleutide prevents the growth of tumors without seriously endangering the main organs. Tumor cell migration can be inhibited by tyroserleutin [2].
|
|---|---|
| ln Vivo |
Tyroserleutide (10-80 μg/kg; intraperitoneally, once daily till mouse death) shown strong antitumor efficacy. Mice implanted with H22 have much longer survival times when tyroserleutin is used [1].
|
| Animal Protocol |
Animal/Disease Models: Female Kunming mouse (18-22 g, 6 weeks old) H22 tumor model [1]
Doses: 10, 20, 40 and 80 μg/kg Route of Administration: Injection (ip) one time/day until mice died. Experimental Results: The survival times of 10, 20, 40 and 80 μg/kg were 25.53±14.14, 25.82±14.29, 30.47±17.89 and 35.06±20.90 days respectively. |
| References |
|
| Molecular Formula |
C18H28CLN3O6
|
|---|---|
| Molecular Weight |
417.884424209595
|
| Exact Mass |
417.166
|
| CAS # |
852982-42-4
|
| Related CAS # |
Tyroserleutide;138168-48-6;Tyroserleutide TFA
|
| PubChem CID |
145925632
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
28
|
| Complexity |
505
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C(C1C=CC(O)=CC=1)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)O)CC(C)C.Cl
|
| InChi Key |
VQJGHKJCNANIKM-WDTSGDEMSA-N
|
| InChi Code |
InChI=1S/C18H27N3O6.ClH/c1-10(2)7-14(18(26)27)20-17(25)15(9-22)21-16(24)13(19)8-11-3-5-12(23)6-4-11;/h3-6,10,13-15,22-23H,7-9,19H2,1-2H3,(H,20,25)(H,21,24)(H,26,27);1H/t13-,14-,15-;/m0./s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~598.26 mM)
H2O : ~2 mg/mL (~4.79 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3930 mL | 11.9652 mL | 23.9303 mL | |
| 5 mM | 0.4786 mL | 2.3930 mL | 4.7861 mL | |
| 10 mM | 0.2393 mL | 1.1965 mL | 2.3930 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
